Oruka Therapeutics (ORKA) Expected to Announce Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) is expected to be releasing its Q1 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Oruka Therapeutics to post earnings of ($0.48) per share for the quarter.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, analysts expect Oruka Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $15.50 on Wednesday. The business has a fifty day moving average of $12.97 and a 200 day moving average of $11.42. The firm has a market capitalization of $580.32 million, a P/E ratio of -3.44 and a beta of -0.35. Oruka Therapeutics has a one year low of $5.49 and a one year high of $52.32.

Hedge Funds Weigh In On Oruka Therapeutics

A hedge fund recently bought a new stake in Oruka Therapeutics stock. Goldman Sachs Group Inc. purchased a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 244,199 shares of the company’s stock, valued at approximately $2,505,000. Goldman Sachs Group Inc. owned 0.65% of Oruka Therapeutics as of its most recent filing with the Securities and Exchange Commission. 56.44% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ORKA has been the topic of several recent research reports. BTIG Research initiated coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They set a “buy” rating on the stock. Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Wednesday, July 23rd. Finally, Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a report on Monday, July 21st. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $40.38.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.